Protalix BioTherapeutics (NYSE:PLX) Shares Down 2.1% – Here’s Why

Protalix BioTherapeutics, Inc. (NYSE:PLX) traded down 2.1% during mid-day trading on Thursday . The company traded as low as $2.27 and last traded at $2.33. 368,279 shares were traded during trading, a decline of 45% from the average session volume of 664,999 shares. The stock had previously closed at $2.38.

Analysts Set New Price Targets

A number of research firms have weighed in on PLX. HC Wainwright boosted their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. StockNews.com lowered Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th.

Protalix BioTherapeutics Trading Up 0.2 %

The firm has a fifty day moving average of $2.29 and a two-hundred day moving average of $1.60. The company has a market cap of $171.94 million, a PE ratio of -17.95 and a beta of 0.75.

Institutional Trading of Protalix BioTherapeutics

A number of institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC raised its holdings in Protalix BioTherapeutics by 33.4% during the 4th quarter. Squarepoint Ops LLC now owns 73,940 shares of the company’s stock valued at $139,000 after acquiring an additional 18,522 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Protalix BioTherapeutics by 13.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company’s stock valued at $101,000 after purchasing an additional 6,434 shares in the last quarter. Millennium Management LLC raised its stake in shares of Protalix BioTherapeutics by 3.8% during the 4th quarter. Millennium Management LLC now owns 387,921 shares of the company’s stock valued at $729,000 after purchasing an additional 14,164 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in Protalix BioTherapeutics by 24.1% during the 4th quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock worth $55,000 after purchasing an additional 5,686 shares in the last quarter. Finally, Jane Street Group LLC boosted its stake in Protalix BioTherapeutics by 147.2% in the 4th quarter. Jane Street Group LLC now owns 113,616 shares of the company’s stock worth $214,000 after purchasing an additional 67,664 shares during the period. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.